Leqembi and the Future of Alzheimer’s Treatment: New Billing Codes and Ongoing Evaluation
The landscape of Alzheimer’s disease treatment is evolving rapidly, with new therapies like Leqembi (lecanemab) gaining approval and prompting adjustments in healthcare billing practices. Recent changes in Germany, detailed in new guidelines, highlight the complexities and emerging standards surrounding this innovative treatment.
New Billing Codes for Genotype Determination
Prior to initiating Leqembi treatment, determining a patient’s ApoE ε4 carrier status is required. A new billing code, 11602 (worth 422 points / 53.76 Euros), has been added to the German billing system (EBM) specifically for this ApoE genotype determination in patients with confirmed early Alzheimer’s disease and demonstrated amyloid-beta pathology.
Extrabudgetary Reimbursement for Infusion Services
The administration of Leqembi itself, delivered bi-weekly as a 60-minute intravenous infusion (with a 2.5-hour post-infusion monitoring period for the initial dose), qualifies for extrabudgetary reimbursement. Healthcare providers must employ codes marked with an “A” – for example, 02101A instead of 02101 – to ensure proper billing.
Specialized Expertise Required
Access to and administration of Leqembi is restricted to specialists. Only neurologists, psychiatrists, or physicians specializing in both neurology and psychiatry, with demonstrated experience in Alzheimer’s disease treatment and access to timely MRI diagnostics, are authorized to order the necessary tests and manage the therapy. This reflects a decision by the German Federal Joint Committee (G-BA).
Leqembi’s Mechanism and Approval Status
Leqembi is the first monoclonal antibody approved in the European Union designed to directly target and remove amyloid-beta plaques in the brain, a hallmark of Alzheimer’s disease. It received approval in September 2025 for treating mild cognitive impairment or early-stage dementia due to Alzheimer’s disease.
No Proven Additional Benefit, But Still Accessible
Despite its approval, the G-BA’s early benefit assessment concluded that the clinical data did not demonstrate an added benefit of Leqembi compared to existing therapies. Still, this assessment only impacts price negotiations with the statutory health insurance fund and does not affect the drug’s availability to patients.
Future Trends in Alzheimer’s Treatment
The introduction of Leqembi signals a broader shift towards disease-modifying therapies for Alzheimer’s. Several key trends are likely to shape the future of treatment:
- Early Detection: Increased emphasis on early diagnosis through biomarkers and advanced imaging techniques, like amyloid PET scans and MRI, will become crucial for identifying candidates for these therapies.
- Personalized Medicine: Genetic testing, such as ApoE ε4 status, will play a larger role in tailoring treatment strategies to individual patients.
- Combination Therapies: Researchers are exploring the potential of combining amyloid-targeting therapies like Leqembi with other approaches that address different aspects of the disease, such as tau pathology or neuroinflammation.
- Digital Health Integration: Remote monitoring and digital cognitive assessments may become integrated into routine care, allowing for more frequent and objective tracking of disease progression and treatment response.
Donanemab, another traditionally approved treatment, also addresses the underlying biology of Alzheimer’s, suggesting a growing focus on targeting the disease’s root causes.
Did you understand?
Leqembi is an antibody intravenous (IV) infusion therapy, meaning it’s administered directly into the bloodstream via an IV line.
FAQ
Q: Is Leqembi a cure for Alzheimer’s?
A: No, Leqembi is not a cure, but This proves the first traditionally approved treatment that aims to modify the disease course in the early stages.
Q: Who is eligible for Leqembi?
A: Individuals with mild cognitive impairment or mild dementia due to Alzheimer’s disease, with confirmed amyloid plaque in the brain.
Q: What is the ApoE ε4 genotype?
A: ApoE ε4 is a genetic variant that increases the risk of developing Alzheimer’s disease. Determining a patient’s status is required before starting Leqembi.
Q: Will insurance cover Leqembi?
A: Coverage will vary depending on the insurance provider, and country. Price negotiations are ongoing.
Q: What are the potential side effects of Leqembi?
A: As with any medication, Leqembi can have side effects. Discuss potential risks and benefits with your healthcare provider.
Pro Tip: If you or a loved one is experiencing memory loss or cognitive changes, consult a neurologist or other qualified healthcare professional for a comprehensive evaluation.
Want to learn more about Alzheimer’s disease and the latest research? Visit the Alzheimer’s Association website for valuable resources and support.
Share your thoughts and experiences in the comments below. What questions do you have about Leqembi and the future of Alzheimer’s treatment?
